1. Scrip

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

Sana, ESSA Pharma, Spero Reveal Strategic Shifts

 
• By Mandy Jackson

Public Company Edition: Syndax received all $350m from its royalty financing up front, while KalVista got $100m initially out of up to $179m. Also, Vera, EyePoint and Eledon grossed $300m, $161m and $85m in follow-on offerings, while Neurogene raised $200m in a private placement.

Finance Watch Public Company
• Source: Alamy

Two and a half months after its first US Food and Drug Administration approval for Incyte Corp.-partnered Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD), Syndax Pharmaceuticals Inc. announced $350m in new financing from Royalty Pharma plc on 4 November to fund the launches of Niktimvo and what may be Syndax’s second FDA approval this year, the menin inhibitor revumenib for KMT2A-rearranged (KMT2Ar) acute leukemias.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Finance Watch

More from Scrip